• Je něco špatně v tomto záznamu ?

Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients

J. Halamkova, I. Kiss, Z. Pavlovsky, J. Tomasek, J. Jarkovsky, Z. Cech, D. Bednarova, S. Tucek, L. Hanakova, M. Moulis, J. Zavrelova, M. Man, P. Benda, O. Robek, Z. Kala, M. Penka,

. 2013 ; 60 (2) : 151-9.

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13024052

Plasminogen activator ihnibitor (PAI 1) belongs to the plasminogen activator system, which is part of the metastatic cascade and significantly contributes to invasive growth and angiogenesis of malignant tumors. Its plasma level is normally low but 4G/4G homozygotes have higher concentrations of PAI 1. This genotype may be associated with worse prognosis and proximal location of colorectal cancer than 5G/5G homozygotes. In our prospective evaluation we examined plasma level PAI 1 (using photometric microplate method ELISA) pre-surgery and, subsequently, 6-8 weeks later, from 80 patients. For the PAI 1 rs1799889 -675 4G/5G polymorphism test the PCR amplification was used.Analysis of collected data was confirmed that significantly higher plasma levels of PAI 1 were found in patients before starting therapy, which decreased (p=0.004) after initiation of treatment. Patients with higher plasma level PAI 1 before (p=0.013) and after therapy (p=0.004) had significantly shorter survival. We found no relationship between polymorphisms of PAI 1 (-675 4G/5G) in relation to stage, survival or tumor location. PAI 1 is useful as a negative marker of prognosis and could be advantageous when planning adjuvant treatment of patients with colorectal carcinoma. Although opinions on the importance of polymorphisms of PAI 1 in relation to the prognosis are not uniform, it does seem that their role in the prognosis of patients with colorectal cancer is not essential.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13024052
003      
CZ-PrNML
005      
20130703125523.0
007      
ta
008      
130703s2013 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2013_020 $2 doi
035    __
$a (PubMed)23259783
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Halamkova, J $u Department of Complex Oncology Care, Masaryk University, Brno, Czech Republic.
245    10
$a Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients / $c J. Halamkova, I. Kiss, Z. Pavlovsky, J. Tomasek, J. Jarkovsky, Z. Cech, D. Bednarova, S. Tucek, L. Hanakova, M. Moulis, J. Zavrelova, M. Man, P. Benda, O. Robek, Z. Kala, M. Penka,
520    9_
$a Plasminogen activator ihnibitor (PAI 1) belongs to the plasminogen activator system, which is part of the metastatic cascade and significantly contributes to invasive growth and angiogenesis of malignant tumors. Its plasma level is normally low but 4G/4G homozygotes have higher concentrations of PAI 1. This genotype may be associated with worse prognosis and proximal location of colorectal cancer than 5G/5G homozygotes. In our prospective evaluation we examined plasma level PAI 1 (using photometric microplate method ELISA) pre-surgery and, subsequently, 6-8 weeks later, from 80 patients. For the PAI 1 rs1799889 -675 4G/5G polymorphism test the PCR amplification was used.Analysis of collected data was confirmed that significantly higher plasma levels of PAI 1 were found in patients before starting therapy, which decreased (p=0.004) after initiation of treatment. Patients with higher plasma level PAI 1 before (p=0.013) and after therapy (p=0.004) had significantly shorter survival. We found no relationship between polymorphisms of PAI 1 (-675 4G/5G) in relation to stage, survival or tumor location. PAI 1 is useful as a negative marker of prognosis and could be advantageous when planning adjuvant treatment of patients with colorectal carcinoma. Although opinions on the importance of polymorphisms of PAI 1 in relation to the prognosis are not uniform, it does seem that their role in the prognosis of patients with colorectal cancer is not essential.
650    _2
$a kolorektální nádory $x genetika $x mortalita $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genotyp $7 D005838
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a inhibitor aktivátoru plazminogenu 1 $x krev $x genetika $7 D017395
650    12
$a polymorfismus genetický $7 D011110
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kiss, I $u -
700    1_
$a Pavlovsky, Z $u -
700    1_
$a Tomasek, J $u -
700    1_
$a Jarkovsky, J $u -
700    1_
$a Cech, Z $u -
700    1_
$a Bednarova, D $u -
700    1_
$a Tucek, S $u -
700    1_
$a Hanakova, L $u -
700    1_
$a Moulis, M $u -
700    1_
$a Zavrelova, J $u -
700    1_
$a Man, M $u -
700    1_
$a Benda, P $u -
700    1_
$a Robek, O $u -
700    1_
$a Kala, Z $u -
700    1_
$a Penka, M $u -
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 60, č. 2 (2013), s. 151-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23259783 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20130703125940 $b ABA008
999    __
$a ok $b bmc $g 987732 $s 822432
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 60 $c 2 $d 151-9 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20130703

Najít záznam

Citační ukazatele

Možnosti archivace